Trial Profile
Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Neflamapimod (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Acronyms VIP
- 19 Jun 2023 Status changed from recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 30 Jan 2021 to 30 Jun 2021.
- 02 Feb 2021 Planned primary completion date changed from 30 Dec 2020 to 30 Apr 2021.